Kalobios, Stemline to debut on Nasdaq
This article was originally published in Scrip
Executive Summary
Two biotech IPOs and Nasdaq listings are scheduled for completion by the end of January. Stemline Therapeutics, a New York-based developer of biopharmaceuticals targeting cancer stem cells and tumors, is aiming to raise up to $38.2 million, while KaloBios Pharmaceuticals of South San Francisco, which is developing engineered monoclonal antibodies to treat respiratory diseases and cancer, is targeting up to $62 million.